JP2021523140A5 - - Google Patents
Info
- Publication number
- JP2021523140A5 JP2021523140A5 JP2020562602A JP2020562602A JP2021523140A5 JP 2021523140 A5 JP2021523140 A5 JP 2021523140A5 JP 2020562602 A JP2020562602 A JP 2020562602A JP 2020562602 A JP2020562602 A JP 2020562602A JP 2021523140 A5 JP2021523140 A5 JP 2021523140A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- sequence
- acid sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667844P | 2018-05-07 | 2018-05-07 | |
| US62/667,844 | 2018-05-07 | ||
| PCT/US2019/030946 WO2019217332A1 (en) | 2018-05-07 | 2019-05-06 | A protein binding nkg2d, cd16 and a tumor-associated antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523140A JP2021523140A (ja) | 2021-09-02 |
| JP2021523140A5 true JP2021523140A5 (https=) | 2022-05-13 |
Family
ID=68468469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562602A Withdrawn JP2021523140A (ja) | 2018-05-07 | 2019-05-06 | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合するタンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210238290A1 (https=) |
| EP (1) | EP3790585A4 (https=) |
| JP (1) | JP2021523140A (https=) |
| KR (1) | KR20210018275A (https=) |
| CN (1) | CN112437672A (https=) |
| WO (1) | WO2019217332A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010536341A (ja) * | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2014198748A1 (en) * | 2013-06-11 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer |
| DE102013019352A1 (de) * | 2013-11-13 | 2015-09-17 | Elke Pogge Von Strandmann | Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort |
| EP4050026A1 (en) * | 2014-04-01 | 2022-08-31 | Adimab, LLC | Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody |
| WO2016001810A1 (en) * | 2014-07-01 | 2016-01-07 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| CA2973720A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| WO2016122701A1 (en) * | 2015-01-26 | 2016-08-04 | Macrogenics, Inc. | Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof |
| DK3313876T3 (da) * | 2015-06-23 | 2025-04-22 | Innate Pharma | Multispecifikke antigenbindende proteiner |
| CA3021634A1 (en) * | 2016-04-15 | 2017-10-19 | Zymeworks Inc. | Multi-specific antigen-binding constructs targeting immunotherapeutics |
| EP3927722A4 (en) * | 2019-02-18 | 2022-11-23 | Courier Therapeutics, Inc. | BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS L-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER |
-
2019
- 2019-05-06 KR KR1020207035135A patent/KR20210018275A/ko not_active Ceased
- 2019-05-06 CN CN201980045240.4A patent/CN112437672A/zh active Pending
- 2019-05-06 US US17/053,558 patent/US20210238290A1/en not_active Abandoned
- 2019-05-06 WO PCT/US2019/030946 patent/WO2019217332A1/en not_active Ceased
- 2019-05-06 EP EP19799447.8A patent/EP3790585A4/en not_active Withdrawn
- 2019-05-06 JP JP2020562602A patent/JP2021523140A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523140A5 (https=) | ||
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2020521448A5 (https=) | ||
| JP2021098733A5 (https=) | ||
| JP2020508997A5 (https=) | ||
| JP2023106433A5 (https=) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2020522474A5 (https=) | ||
| JP2021534096A5 (https=) | ||
| JP2021035388A5 (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2020522473A5 (https=) | ||
| JP2021098732A5 (https=) | ||
| JP2023052214A5 (https=) | ||
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2021512630A5 (https=) | ||
| JP2021523913A5 (https=) | ||
| JP2019536430A5 (https=) | ||
| JP2022551969A5 (https=) | ||
| JP2020510646A5 (https=) | ||
| JP2021533169A5 (https=) | ||
| RU2019128134A (ru) | Антитело против gprc5d и молекула, содержащая антитело | |
| JP2023509448A5 (https=) | ||
| JP2020507577A5 (https=) |